Drug Chatter -- Tracking biopharma stock chatter

Profile for Osiris Therapeutics, Inc. (OSIR)

« Back to company index

OSIR Chatter Timeline

Stock Ticker for OSIR

Most Active Tweeters for OSIR

UserTweets
@dispatchtribune 1
@TheMarketsDaily 1
@registrarjourn 1
@ThisLincolnian 1
@biotechfan20 1

Recent Tweets for OSIR

dispatchtribune @dispatchtribune
Osiris Therapeutics $OSIR and Editas Medicine $EDIT Head to Head Comparison https://t.co/b55ACSIKI9
May 24th 2018, 2:05pm
ThisLincolnian @ThisLincolnian
Osiris Therapeutics $OSIR versus Editas Medicine $EDIT Head-To-Head Comparison https://t.co/duKUHu6iNt
May 20th 2018, 6:05am
biotechfan20 @biotechfan20
It is fascinating how a company like $XON (Intrexon) trades at 9.5X revenue whereas $OSIR trades at 2.1X. Peter Fr… https://t.co/yohF8FQkD1
May 17th 2018, 12:05pm
TickerReport @TickerReport
Osiris Therapeutics $OSIR & Editas Medicine $EDIT Head-To-Head Review https://t.co/g8lOP8BkTT
May 17th 2018, 10:05am
ConsumerFeed @ConsumerFeed
Osiris Therapeutics $OSIR and Organovo $ONVO Critical Review https://t.co/H8ihtDLMzS
May 15th 2018, 4:05pm
registrarjourn @registrarjourn
Osiris Therapeutics $OSIR and Organovo $ONVO Critical Review https://t.co/nRNh0MEJnc
May 15th 2018, 10:05am
TheMarketsDaily @TheMarketsDaily
Comparing Osiris Therapeutics $OSIR and Organovo $ONVO https://t.co/KUjNEHCdlM
May 13th 2018, 1:05pm
confcalltran @confcalltran
Osiris Therapeutics's Interim CFO just declared ownership of no shares of Osiris Therapeutics https://t.co/kbclXN2lF3 $OSIR
May 11th 2018, 7:05pm
StockTexts @StockTexts
$OSIR Osiris Therapeutics, Inc. SEC Filing: Form 3 https://t.co/AYuXMVysa6
May 11th 2018, 6:05pm
Allstocknews @Allstocknews
$OSIR New Form DEF 14A for Osiris Therapeutics, Inc. From our Stock News Alerts App
May 11th 2018, 2:05pm
Allstocknews @Allstocknews
$OSIR New Form DEFA14A for Osiris Therapeutics, Inc. From our Stock News Alerts App
May 11th 2018, 2:05pm
StockTexts @StockTexts
$OSIR Osiris Therapeutics, Inc. SEC Filing: Form DEF 14A https://t.co/GlZ8B2qbYA
May 11th 2018, 2:05pm
biotechfan20 @biotechfan20
$OSIR Gross Profit Margin 72% for the three months ended March 31, 2018 and 71% for the three months ended March 31, 2017.
May 11th 2018, 8:05am
biotechfan20 @biotechfan20
$OSIR 10-Q Shareholder Derivative Actions "The Company has reached an agreement-in-principle with the plaintiffs in… https://t.co/de4wFWANmO
May 11th 2018, 8:05am
GreenMonsterah @GreenMonsterah
RT @UnknownPatriot7: This will make $OSIR look like Altar Boys IMHO... How can you even find a starting point for restatement? https://t.c…
May 10th 2018, 10:05pm
UnknownPatriot7 @UnknownPatriot7
This will make $OSIR look like Altar Boys IMHO... How can you even find a starting point for restatement? https://t.co/aY2CrfjVeF
May 10th 2018, 6:05pm
Allstocknews @Allstocknews
$OSIR New Form 10-Q for Osiris Therapeutics, Inc. From our Stock News Alerts App
May 10th 2018, 4:05pm
Allstocknews @Allstocknews
$OSIR New Form 8-K for Osiris Therapeutics, Inc. From our Stock News Alerts App
May 10th 2018, 4:05pm
biotechfan20 @biotechfan20
Will $OSIR Q1 2018 revenue be influenced by the 17% increase in Sales & Marketing expenditures in Q4 2017? First m… https://t.co/3JyR1ShzO6
May 8th 2018, 2:05pm
biotechfan20 @biotechfan20
$OSIR first quarter ended March 31. SEC rules allow 40 days to report Q1 results. 40 days = Wednesday May 9th.
May 8th 2018, 2:05pm
biotechfan20 @biotechfan20
#NASDAQ takes 4-6 weeks to approve a relisting application, lets hope $OSIR submitted shortly after filing the 10K on March 28, 2018.
May 8th 2018, 2:05pm
UnknownPatriot7 @UnknownPatriot7
@Ballwhacker @MotherCabriniNY $OSIR plunged 57% over a 9 day span in March 2017 after delist announcement. https://t.co/z9ZAxqQ2yz
May 1st 2018, 10:05pm
biotechfan20 @biotechfan20
Nurse-manager Dill “If it’s a venous leg ulcer, you wrap it. We use Grafix a lot,..." https://t.co/0t68DSAs7s $OSIR #VLU #wound
May 1st 2018, 6:05pm
WatchlistN @WatchlistN
Head-To-Head Review: Adverum Biotechnologies $ADVM & Osiris Therapeutics $OSIR https://t.co/59tS9y8g5W
May 1st 2018, 3:05pm
ThisLincolnian @ThisLincolnian
Head-To-Head Review: Adverum Biotechnologies $ADVM & Osiris Therapeutics $OSIR https://t.co/lLcao3qHbb
May 1st 2018, 3:05pm
TranscriptDaily @TranscriptDaily
Reviewing Adverum Biotechnologies $ADVM and Osiris Therapeutics $OSIR https://t.co/qRYxmePxgi
April 29th 2018, 11:04am
ledgerzette @ledgerzette
Reviewing Adverum Biotechnologies $ADVM and Osiris Therapeutics $OSIR https://t.co/YkiShqxX3X
April 29th 2018, 11:04am
UnknownPatriot7 @UnknownPatriot7
Has $MDXG ever done a study comparable to $OSIR? https://t.co/heTzMLGIYF
April 27th 2018, 8:04pm
biotechfan20 @biotechfan20
$OSIR Announces New Peer-Reviewed Publication Summarizing Clinical Outcomes of Viable Cryopreserved Placental Membr… https://t.co/WCWyHgaOll
April 25th 2018, 5:04pm
otcdynamics @otcdynamics
$OSIR Osiris Announces New Peer-Reviewed Publication Summarizing Clinical Outcomes of Viable Cryopreserved Placental https://t.co/WaZtyfFHRt
April 25th 2018, 4:04pm
StockWolfCom @StockWolfCom
$OSIR Osiris Announces New Peer-Reviewed Publication Summarizing Clinical Outcomes of Viable Cryopreserved Placenta… https://t.co/yeAP4vMMct
April 25th 2018, 4:04pm
GNWLive @GNWLive
Osiris Announces New Peer-Reviewed Publication Summarizing Clinical Outcomes of Viable Cryopreserved $OSIR https://t.co/5Ybe6Y5DA8
April 25th 2018, 4:04pm
mikea1028 @mikea1028
RT @biotechfan20: $OSIR to Present Clinical and Scientific Studies at Symposium on Advanced Wound Care and Wound Healing Society Spring Con…
April 24th 2018, 7:04pm
biotechfan20 @biotechfan20
$OSIR to Present Clinical and Scientific Studies at Symposium on Advanced Wound Care and Wound Healing Society Spri… https://t.co/ajXFemC8a0
April 24th 2018, 7:04pm
otcdynamics @otcdynamics
$OSIR Osiris Therapeutics to Present Clinical and Scientific Studies at Symposium on Advanced Wound Care and Wound https://t.co/zoafBzzKAG
April 24th 2018, 4:04pm
GNWLive @GNWLive
Osiris Therapeutics to Present Clinical and Scientific Studies at Symposium on Advanced Wound Care and $OSIR https://t.co/owcfp51VP4
April 24th 2018, 4:04pm
biotechfan20 @biotechfan20
$OSIR stockholders are being asked to vote on a long-term cash-based incentive compensation program. Up to 15% of n… https://t.co/QFTRgCykKG
April 24th 2018, 10:04am
Allstocknews @Allstocknews
$OSIR New Form PRE 14A for Osiris Therapeutics, Inc. From our Stock News Alerts App
April 23rd 2018, 5:04pm
confcalltran @confcalltran
Other preliminary proxy statements https://t.co/HMsImkA5J2 $OSIR
April 23rd 2018, 5:04pm
dakotafinancial @dakotafinancial
Osiris Therapeutics $OSIR vs. Bio-Techne $TECH Head to Head Review https://t.co/3Xehr8PBsV
April 23rd 2018, 2:04pm
ThisLincolnian @ThisLincolnian
Comparing Bio-Techne $TECH and Osiris Therapeutics $OSIR https://t.co/6tYqmjqMA6
April 23rd 2018, 2:04pm
biotechfan20 @biotechfan20
@mikea1028 I am looking forward to $OSIR relisting on #Nasdaq
April 21st 2018, 9:04am
biotechfan20 @biotechfan20
$OSIR 2018 Meeting of Stockholders scheduled for 9am June 26, 2018 https://t.co/fYZxFdiNS1 Well done Osiris Therapeutics!
April 19th 2018, 5:04pm
confcalltran @confcalltran
Date of the 2018 Annual Meeting of https://t.co/18txRcBPTk $OSIR
April 19th 2018, 4:04pm
StockTexts @StockTexts
$OSIR Osiris Therapeutics, Inc. SEC Filing: Form 8-K https://t.co/pGnS1Gxrj8
April 19th 2018, 4:04pm
livetraderalrt @livetraderalrt
$OSIR 1.7m ago: Current event(s) report - Other Events https://t.co/0YjFYRqmd5
April 19th 2018, 4:04pm
WatchlistN @WatchlistN
Head-To-Head Contrast: Bio-Techne $TECH vs. Osiris Therapeutics $OSIR https://t.co/t77gXnDMZu
April 19th 2018, 2:04am
DPolitical @DPolitical
$TECH, $OSIR - Comparing Bio-Techne #TECH & Osiris Therapeutics #OSIR https://t.co/0KVmgHYUev
April 16th 2018, 7:04pm
dailypoliticaln @dailypoliticaln
Comparing Bio-Techne $TECH & Osiris Therapeutics $OSIR https://t.co/dmHLDHcoO9
April 16th 2018, 7:04pm
biotechfan20 @biotechfan20
Osiris Therapeutics: Regenerated https://t.co/stiXJ76Bul Location: @ColumbiaMD $OSIR Strategic Partners: $MESO… https://t.co/ktozrKm93g
April 13th 2018, 2:04pm

Contact © thinkBiotech LLC 2004 - 2018. All rights reserved.